Diagnosing Sexual Dysfunction in Men and Women: Sexual History Taking and the Role of Symptom Scales and Questionnaires

Hatzichristou, D.; Kirana, Paraskevi‐Sofia; Banner, Linda; Althof, Stanley E.; Lonnée-Hoffmann, Risa; Dennerstein, Lorraine; Rosen, Raymond C.

doi:10.1016/j.jsxm.2016.05.017

Cited by 121 publications

(61 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Convergent validity using IELT as the standard was excellent: control domain (0.75), sexual satisfaction domain (0.60), and distress domain (0.68). Known-groups validity was adequate, all domain mean scores were statistically significantly worse in men with PE compared with the men reporting no PE problems (16). …”

Section: Premature Ejaculation (Pe) Patient Reported Outcome (Pros)mentioning

confidence: 95%

Patient reported outcomes in the assessment of premature ejaculation

Althof¹

2016

Transl. Androl. Urol.

Self Cite

View full text Add to dashboard Cite

The term ‘Patient Reported Outcome’, abbreviated as PRO, was introduced by the US Food and Drug Administration (FDA) which proposed guidance on the development and validation of PROs. Previously PROs were known as self-report diaries, event-logs, self-administered questionnaires, and clinician administered rating scales. PROs seek to capture the subjective perceptions of patients and/or partner’s related to their specific symptoms, degree of bother, efficacy of a medication or psychotherapy intervention, and quality of life issues related to a specific condition. This article reviews the essential psychometric and regulatory agency requirements in the development of PROs. The constructs of reliability, various forms of validity, sensitivity, and specificity as well as concerns with translating a PRO into a different language are reviewed. Three PROs, the Premature Ejaculation Profile (PEP), the Index of Premature Ejaculation (IPE) and the Premature Ejaculation Diagnostic Tool (PEDT) all used in the assessment of premature ejaculation (PE) are discussed. These questionnaires meet or exceed all the psychometric requirements and have been employed in clinical trials and observational studies of men with PE. The article concludes on discussing some of the limitations of PRO use and recommendations for the future.

show abstract

Section: Premature Ejaculation (Pe) Patient Reported Outcome (Pros)mentioning

confidence: 95%

Patient reported outcomes in the assessment of premature ejaculation

Althof¹

2016

Transl. Androl. Urol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Surgical interventions to the prostate also have an impact on erectile function according to the type of surgery that was performed [45]. Epidemiologically, there are other risk factors that potentially associate to ED, including psoriasis [46][47][48], gouty arthritis [49,50], ankylosing spondylitis [51], nonalcoholic fatty liver [52], chronic liver disorders [53], chronic periodontitis [54], open-angle glaucoma [55], inflammatory bowel disease [56], and complications following transrectal ultrasound (TRUS) guided prostate biopsy [57].…”

Section: Sexual Dysfunctionmentioning

confidence: 99%

Lower Urinary Tract Symptoms (LUTS) and Sexual Function and Dysfunction

Konstantinidis¹,

Eleftheropoulos²,

Karafotias³

2020

Lower Urinary Tract Dysfunction - From Evidence to Clinical Practice

View full text Add to dashboard Cite

In recent years, the coexistence of sexual dysfunction (SD) and lower urinary tract symptoms (LUTS) has become a popular topic for researchers. Numerous clinical epidemiologic studies have been planned for this reason and have evaluated the relationship between these seemingly irrelevant urological conditions. The connection between SD and LUTS has already been acknowledged, and common pathophysiological pathways have been recognized. In this chapter was attempted to evaluate the impact on patient's quality of life (QoL), common pathophysiological pathways and therapy aspects of this condition. SD and LUTS are common problems among the general population and affect a great percentage of urological patients. It is a subject that affects the community in social, financial, and psychological terms. In this case, research for new treatment options has been triggered as phosphodiesterase type 5 inhibitors established their role as the widely approved combination therapy.

show abstract

“…As addressed above, female sexual dysfunction is complex and, therefore, poses challenges in quantitative workup; the use of standardized and validated questionnaires has been recommended to aid the evaluation of female sexual dysfunction. 4,5 In addition to reduced fertility, 6 women with C-CAH and NC-CAH also frequently present with significantly impaired sexual function compared to controls, particularly in the domains of lubrication, satisfaction, and pain. 7,8 In girls with C-CAH and severe sexual ambiguity, genital reconstructive surgery is frequently performed in infancy and may, at least in part, add to sexual dysfunction due to lack of genital sensitivity, difficulties in vaginal lubrication, or pain during vaginal intercourse.…”

Section: Within the Diagnostic And Statistical Manual Of Mentalmentioning

confidence: 99%

Influence of Genotype and Hyperandrogenism on Sexual Function in Women With Congenital Adrenal Hyperplasia

Schernthaner-Reiter

Baumgartner‐Parzer

Egarter

et al. 2019

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Background: Depending on CYP21A2 genotype, congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency leads to biochemical alterations (including hyperandrogenism, hypocortisolism, and hypoaldosteronism) and a wide spectrum of phenotypic disease manifestation. The latter include life-threatening salt-wasting crises, prenatal virilization of genitalia in women (classic CAH [C-CAH]) as well as milder forms of the disease exclusively presenting with hirsutism, acne or reduced fertility (nonclassic CAH [NC-CAH]), and could influence sexual function and identity. Aim: The present study evaluated sexual function, gender identification, and partner preference in women with C-CAH and NC-CAH. Methods: In a cross-sectional cohort analysis, 35 female patients with CAH were divided into 2 groups: C-CAH (salt-wasting/simple virilizing; n ¼ 17) and NC-CAH (n ¼ 18) according to genotype and phenotype. Sexual function and sexual distress were assessed using established questionnaires, including the Female Sexual Function Index. Phenotype (defined by signs of hyperandrogenism) was assessed clinically (Ferriman-Gallwey score) and with the ovulatory function index. CYP21A2 genotype was determined by Sanger sequencing and multiplex ligation-dependent probe amplification. Sexual function was also separately analyzed in the context of clinical signs of androgenization in women with (n ¼ 13) and without acne (n ¼ 22). Outcomes: The study outcomes were sexual function and sexual distress in relation to genotype, clinical signs of androgenization, and biochemical parameters. Results: Women with NC-CAH had significantly lower orgasm scores, a trend toward lower sexual function with higher sexual distress, as well as biochemical evidence of hyperandrogenism (higher dehydroepiandrosterone sulfate and lower SHBG) and a trend toward more clinical signs of hyperandrogenism (hirsutism). Indicators of in utero and childhood androgen excess as well as the presence of acne in all patients were related to lower sexual function and higher sexual distress. Clinical signs of hyperandrogenism correlated well with cardiovascular and metabolic risk factors. Clinical Translation: Women with NC-CAH and women with clinical signs of hyperandrogenism demonstrated higher distress compared to women with C-CAH and women without clinical signs of hyperandrogenism, respectively, regarding different aspects of sexual function. Conclusions: These data underline the importance of early diagnosis and therapy initiation, especially in patients with NC-CAH.

show abstract

Diagnosing Sexual Dysfunction in Men and Women: Sexual History Taking and the Role of Symptom Scales and Questionnaires

Cited by 121 publications

References 48 publications

Patient reported outcomes in the assessment of premature ejaculation

Patient reported outcomes in the assessment of premature ejaculation

Lower Urinary Tract Symptoms (LUTS) and Sexual Function and Dysfunction

Influence of Genotype and Hyperandrogenism on Sexual Function in Women With Congenital Adrenal Hyperplasia

Contact Info

Product

Resources

About